The Early Embryo Viability Assessment (Eeva) test is the first and only non-invasive IVF test clinically proven to increase the accuracy of predicting viable embryos at an early stage. The Eeva test was developed based on landmark research conducted at Stanford University, in the United States, which discovered that early cell division timings are an accurate predictor of viability and underlying health of the embryo.
At the heart of Eeva is intelligent software that reliably and consistently assesses critical and subtle differences in early embryo development, with the help of time-lapse photography. This data helps embryologists and IVF clinicians determine an embryo’s viability, and to select the embryos with the highest potential for transfer or freezing. Eeva is designed to safely identify which embryos are most likely to develop to blastocyst stage – a critical stage in embryo development that typically happens on ‘day’ 5 or 6. With access to this unique information, your IVF team can more accurately select the best embryo(s) for transfer, and this could improve your chances for a successful pregnancy.
There are many factors that contribute to a successful live birth, but identifying viable embryos in the first few days is one of the most critical. The benefits of Eeva include:
Whether you are on your first IVF cycle or second, Eeva is suitable for all patients undergoing IVF treatment. By providing access to critical and subtle differences in the early stages of embryo development, Eeva provides embryologists and consultants with objective information about the underlying health of the embryo. This information is critical in making informed decisions about your treatment path.
GCRM was proud to be amongst the first clinics in the world to offer this new test, if you want to know more, please call the clinic on 0141 891 8749.